LAS VEGAS, December 27, 2017 /PRNewswire/ --
As we near the end of 2017, biotech companies are preparing for the first quarter of the New Year. As time progresses we continue to witness technology change lives in every possible way, biotechnology is one of the leading fields of technology and is changing modern medicine. Advancements in medicine happen at an increasing rate and technology creates new treatments that are developed faster than ever. This allows new therapies and drugs to be tested more quickly with results shared faster than ever before. Electroceutical therapy is one area within biotechnology that many experts consider to be a critical component of the future of medicine.
Biotech companies researching and developing electroceutical therapies will likely see an exciting first quarter of 2018. You may be wondering what this type of treatment is if you are not already familiar with it? Well, it is a procedure that uses an electrical stimulation of the nerves in the body in order to treat a variety of conditions. This procedure is thought to succeed where traditional treatments have failed. Organizations throughout the medical community are supporting this therapy in a huge way. For example, in 2014 the National Institute of Health (NIH) made a $248M investment to map the electrical wiring of the human body and research this type of therapy.
Now here are several biotech's that are sprinting into the New Year: Endonovo Therapeutics, Inc. (OTC: ENDV), La Jolla Pharmaceutical Company (NASDAQ: LJPC), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Gilead Sciences, Inc. (NASDAQ: GILD), and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) featured below.
Endonovo Therapeutics, Inc. (OTCQB: ENDV)
Market Cap: 21.369, Current Share Price: $0.07
ENDV is a clinical-stage developer of non-invasive medical devices called Electroceuticals, which use electrical stimulation to treat disease by reducing inflammation in tissues and organs. The company is concentrated on cardiovascular and cerebrovascular diseases, like stroke. The Company recently announced it has acquired the assets of Rio Grande Neurosciences, a privately-held developer of non-invasive brain stimulation technology for the treatment of CNS disorders. The technology, targeted-Pulsed Electromagnetic Fields (tPEMF), uses radiofrequency (RF) waves at 27.12 MHz to deliver electromagnetic energy to the brain in order to reduce neuroinflammation for the treatment of CNS disorders, such as stroke, traumatic brain injury (TBI), and chronic traumatic encephalopathy (CTE), which have garnered a lot of attention recently because of how many NFL players suffer from concussions and CTE. The technology is a potential blockbuster therapy for CNS disorders because it is a portable, low-power medical device that has shown very strong pre-clinical data in animal models of stroke, traumatic brain injury and experimental autoimmune encephalomyelitis. Unlike drugs, which are nearly impossible to deliver into the brain because of the blood-brain-barrier (BBB), tPEMF therapy is not limited by this issue because it is not a drug, but rather a non-invasive medical device. tPEMF is expected to treat mild TBI "secondary injury" by reducing neuroinflammation and enhancing blood flow, thereby reducing neuropathology.
ENDV is taking over the management and funding of currently planned clinical trials and will initiate additional clinical trials to evaluate tPEMF for the treatment of traumatic brain injury, post-concussion syndrome, stroke and multiple sclerosis. ENDV has also stated that it plans to uplist its common stock onto a national stock exchange, look out for news regarding the uplist. The strong data and the differentiated nature of tPEMF technology makes ENDV a potential blockbuster in the CNS therapy market and an extremely attractive opportunity for investors.
La Jolla Pharmaceutical Company, (NASDAQ: LJPC)
Market Cap: $734.003M, current share price: $33.19
The end of the year marks an exciting time for LJPC as far as drug approvals with the FDA are concerned. The Company's lead drug GiaprezaTM targets an indication of low blood pressure in patients with septic or other distributive shock. Last week, the FDA announce it was approved the drug in its target indication. The company wants to get the asset on shelves in the first quarter of next year.
Celldex Therapeutics, Inc. (NASDAQ: CLDX)
Market Cap: $94.783B, current share price: $72.56
With CDLX, lets take a look at this year's earnings compared to last year. The most recent twelve-month earnings performed at -$121.5M. In relation to last year's figure, it has actually become less negative. Revenue growth over past couple of years has been negative at -7.54%. The key to profitability here is to make sure the Company's cost growth is well-controlled. Eyeballing growth from a sector-level, the US biotechnology industry has been growing its average earnings by double-digit 11.07% over the previous twelve months, and 20.18% over the past five. Showing an exciting advantage for CLDX in the next few years. It will be important to track this company in the first quarter of 2018 to see if their earnings continue on the less negative track.
Gilead Sciences, Inc. (NASDAQ: GILD)
Market Cap: $94.796B, current share price: $72.57
So for GILD it looks as though they are not sprinting into the new year. 2017 was a rough year and analysts expect the Company's top line to fall 15% and forecast EPS (earnings per share) of $8.70. GILD stock price has risen -1.9% over the last 12 months and -5.5% this year. Analysts estimate that the stock could return -13.3% over the next 12 months, and have given a 12 month target price of $85.70 per share. Making the first quarter of 2018 quite grim for GILD.
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
Market Cap: $15.347M, current share price: $.31
Leadership change at SPPI was announced last week that its Board of Directors has terminated Rajesh C. Shrotriya, MD without cause from his position as Chief Executive Officer. They appointed Joseph W. Turgeon as President and Chief Executive Officer. Mr. Turgeon brings more than 30 years of experience in the pharmaceutical industry, including various executive leadership roles at Amgen Inc. Leadership changes such as this bring about interesting change that could be reflected the first quarter of 2018.
Content Provided By: Microcap Speculators
DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand FinancialNewsMedia.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
FN Media Group LLC